Log in

NYSE:NVSNovartis Stock Price, Forecast & News

$84.91
-0.08 (-0.09 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$83.51
Now: $84.91
$84.93
50-Day Range
$80.93
MA: $85.69
$89.78
52-Week Range
$69.18
Now: $84.91
$99.84
Volume1.36 million shs
Average Volume1.87 million shs
Market Capitalization$194.60 billion
P/E Ratio16.20
Dividend Yield2.36%
Beta0.51
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; and TRIO. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Read More
Novartis logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.3Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.19 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone41-61-324-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$47.50 billion
Cash Flow$7.80 per share
Book Value$22.24 per share

Profitability

Net Income$11.73 billion

Miscellaneous

Employees103,914
Outstanding Shares2,291,800,000
Market Cap$194.60 billion
Next Earnings Date7/16/2020 (Estimated)
OptionableOptionable

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Novartis (NYSE:NVS) Frequently Asked Questions

How has Novartis' stock been impacted by COVID-19 (Coronavirus)?

Novartis' stock was trading at $82.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVS shares have increased by 3.4% and is now trading at $84.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Novartis?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Novartis.

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Thursday, July 16th 2020. View our earnings forecast for Novartis.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Tuesday, April, 28th. The company reported $1.56 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.37 by $0.19. The firm earned $12.28 billion during the quarter, compared to analysts' expectations of $11.92 billion. Novartis had a net margin of 24.97% and a return on equity of 24.39%. The business's revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.21 EPS. View Novartis' earnings history.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Monday, February 3rd. Stockholders of record on Wednesday, March 4th will be given a dividend of $3.0425 per share on Thursday, March 12th. This represents a yield of 2%. The ex-dividend date is Tuesday, March 3rd. This is an increase from Novartis's previous annual dividend of $2.86. View Novartis' dividend history.

What price target have analysts set for NVS?

11 brokers have issued 1-year price targets for Novartis' shares. Their forecasts range from $100.00 to $116.00. On average, they anticipate Novartis' share price to reach $107.00 in the next year. This suggests a possible upside of 26.0% from the stock's current price. View analysts' price targets for Novartis.

Has Novartis been receiving favorable news coverage?

News coverage about NVS stock has trended extremely negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novartis earned a media sentiment score of -4.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutNovartis.

Are investors shorting Novartis?

Novartis saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,820,000 shares, a decrease of 8.1% from the April 30th total of 3,070,000 shares. Based on an average daily trading volume, of 2,830,000 shares, the short-interest ratio is presently 1.0 days. Currently, 0.1% of the company's stock are short sold. View Novartis' Current Options Chain.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Intel (INTC), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Cisco Systems (CSCO), Gilead Sciences (GILD), NVIDIA (NVDA) and Merck & Co., Inc. (MRK).

Who are Novartis' key executives?

Novartis' management team includes the following people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 54)
  • Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
  • Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (1.05%), Loomis Sayles & Co. L P (0.45%), Franklin Resources Inc. (0.39%), Fisher Asset Management LLC (0.37%), Mawer Investment Management Ltd. (0.34%) and Wells Fargo & Company MN (0.29%).

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Jennison Associates LLC, Primecap Management Co. CA, Janus Henderson Group PLC, Capital Research Global Investors, Voloridge Investment Management LLC, and Schafer Cullen Capital Management Inc.

Which institutional investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including Mawer Investment Management Ltd., Fred Alger Management LLC, Morgan Stanley, Capital International Investors, Two Sigma Investments LP, Wellington Management Group LLP, Bartlett & Co. LLC, and Advisor Group Holdings Inc..

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $84.91.

How big of a company is Novartis?

Novartis has a market capitalization of $194.60 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 103,914 workers across the globe.

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.